Magazine article Drug Topics

Help for Transplant Patients

Magazine article Drug Topics

Help for Transplant Patients

Article excerpt

Lawmakers in Washington, D.C., recently unveiled a bill that would require Medicare to pay for antirejection drugs needed by recipients of organ transplants.

Medicare will pay for immunosuppressive drugs for eligible patients for three years. After that, transplant recipients will pay up to $1,000 per month for the drugs, which they're required to take for the rest of their lives to prevent their bodies from rejecting the donated organ.

Rep. Karen Thurman, a Florida Democrat who is one of the sponsors of the bill, said she knows of kidney patients who cannot afford the drugs, suffer organ failure, "and then go back once more to an awful time" of undergoing dialysis while hoping for a second transplant.

She and the other cosponsors, including Rep. Charles Canady (R., Fla.) and Sen. Mike DeWine (R., Ohio), contend that it makes little sense for Medicare to pay for organ transplants but not the follow-up care. They claimed that if a transplant fails because someone cut back on drugs, Medicare could end up spending even more for hospitalization, a second transplant, and dialysis in the case of kidney patients.

AIDS agent shows promise Two clinical trials have indicated that Preveon (adefovir dipivoxil, Gilead Sciences Inc.), an investigational, once-daily, orally administered reverse transcriptase inhibitor under development for the potential treatment of HIV, is effective in a 60mg dose. Results showed that treatment with 60-mg monotherapy provides significant anti-HIV activity compared with placebo in treatment-naive patients and that combination regimens comparing 60- and 120-mg doses of the drug show similar antiviral effects in treatment-experienced patients. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.